RESUMEN
The aim of this study was to investigate the dermoscopic changes in acquired melanocytic naevi in a large paediatric population over an interval of several years. Images of 717 melanocytic naevi were obtained from 160 consecutive patients. Dermoscopic pigment pattern changes were observed in one of two lesions after a follow-up of one year, in 34 of 295 lesions (11.5%) after 2 years, in 40 of 190 lesions (21.1%) after 3 years, in 40 of 141 lesions (28.4%) after 4 years, in 5 of 37 lesions (13.5%) after 5 years, in 12 of 31 lesions (38.8%) after 6 years, and in 7 of 21 lesions (33.3%) after 7 years. Dermoscopic changes were detected in 25.3% of the lesions in patients aged 3-6 years, in 21% of the lesions in patients aged 7-12 years, and in 15.5% of the lesions in patients over 13 years. Main pattern changes consisted of transition from globular to globular-reticular (35 naevi), from globular to reticular (14 naevi) and from globular-reticular to reticular (24 naevi). These results are consistent with the view that melanocytic naevi generally undergo a characteristic transition from a globular pattern to a reticular pattern. Most of the changes are observed in the 3-6 years age group when hormonal and/or environmental factors are not thought to play a role in pattern alterations.
Asunto(s)
Dermoscopía , Nevo Pigmentado/patología , Neoplasias Cutáneas/patología , Adolescente , Factores de Edad , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Italia , Masculino , Valor Predictivo de las Pruebas , Pronóstico , Pigmentación de la Piel , Factores de TiempoRESUMEN
Erythroderma is a scaling erythematous dermatitis involving 90% or more of the cutaneous surface. Psoriasis and eczema are the most common dermatoses underlying erythroderma. Cutaneous T cell lymphomas can also cause erythroderma. Differential diagnosis between psoriatic erythroderma and lymphomatous erythroderma is often challenging. Tumour necrosis factor-alpha inhibitors are a new class of drugs used in the treatment of psoriasis, even in erythrodermic psoriasis. The effects of anti-tumour necrosis factor-alpha in cutaneous T cell lymphomas have not yet been established. Consequently, it is mandatory to treat an erythrodermic psoriatic patient with tumour necrosis factor-alpha blockers only if a lymphoproliferative cutaneous disorder has been excluded.
Asunto(s)
Dermatitis Exfoliativa/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adalimumab , Antiinflamatorios/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Dermatitis Exfoliativa/etiología , Eccema/complicaciones , Etanercept , Humanos , Inmunoglobulina G/uso terapéutico , Infliximab , Linfoma Cutáneo de Células T/complicaciones , Psoriasis/complicaciones , Receptores del Factor de Necrosis Tumoral/uso terapéuticoRESUMEN
BACKGROUND: The first step in the analysis of a dermatoscopically imaged melanocytic lesion is segmentation--informally, isolating those points in the image belonging to the lesion from those belonging to the surrounding non-lesional skin. Although typically studied in the context of automated analysis, segmentation is a necessary step even for human operators who plan to evaluate quantitative features of a lesion (such as diameter or asymmetry). METHODS: In a double blind evaluation of the segmentation of 77 digital dermatoscopic images, we observed a significant inter-operator variability. RESULTS: The area of the disagreement region was on average 15.28% of the area of the lesion itself, and in 10% of the cases it was more than 28%. More experienced dermatologists showed greater agreement among themselves than with less experienced dermatologists, and a slight tendency toward 'tighter' segmentations. CONCLUSION: The evaluation methodology addresses a number of crucial difficulties encountered in previous studies and may be of independent interest. Our results underscore the necessity of taking into account inter-operator variability in large epidemiological studies, in particular those involving less experienced dermatologists, and of striving toward techniques allowing greater standardization and replicability in the evaluation of the fundamental visual parameters of lesions.
Asunto(s)
Dermoscopía/métodos , Nevo Pigmentado/patología , Procesamiento de Señales Asistido por Computador , Neoplasias Cutáneas/patología , Método Doble Ciego , Femenino , Humanos , Masculino , Variaciones Dependientes del Observador , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
UV-irradiated skin and UV-induced tumors overexpress the inducible isoform of cyclooxygenase-2 (Cox-2), and Cox-2 inhibition reduces photocarcinogenesis. To evaluate photoprotective effects of Polypodium leucotomos extract (PL), hairless Xpc(+/-) mice were fed for 10 days with PL (300 mg/kg) or vehicle then UV-irradiated, once. By 24 hours, UV-induced Cox-2 levels were increased in vehicle-fed and PL-fed mice, whereas by 48 and 72 hours, Cox-2 levels were four- to fivefold lower in PL-fed mice (P < 0.05). p53 expression/activity was increased in PL-fed versus vehicle-fed then UV-irradiated mice. UV-induced inflammation was decreased in PL-fed mice, as shown by approximately 60% decrease (P < 0.001) in neutrophil infiltration at 24 hours, and macrophages by approximately 50% (<0.02) at 24 and 48 hours. By 72 hours, 54 +/- 5% cyclobutane pyrimidine dimers remained in vehicle-fed versus 31 +/- 5% in PL-fed skin (P < 0.003). The number of 8-hydroxy-2'-deoxyguanosine-positive cells were decreased before UV irradiation by approximately 36% (P < 0.01), suggesting that PL reduces constitutive oxidative DNA damage. By 6 and 24 hours, the number of 8-hydroxy-2'-deoxyguanosine-positive cells were approximately 59% (P < 0.01) and approximately 79% (P < 0.03) lower in PL-fed versus vehicle-fed mice. Finally, UV-induced mutations in PL-fed-mice were decreased by approximately 25% when assessed 2 weeks after the single UV exposure. These data demonstrate that PL extract supplementation affords the following photoprotective effects: p53 activation and reduction of acute inflammation via Cox-2 enzyme inhibition, increased cyclobutane pyrimidine dimer removal, and reduction of oxidative DNA damage.
Asunto(s)
Ciclooxigenasa 2/metabolismo , Reparación del ADN , Inflamación , Ratones Pelados , Mutagénesis , Extractos Vegetales/farmacología , Polypodium/química , 8-Hidroxi-2'-Desoxicoguanosina , Animales , Análisis Mutacional de ADN , Reparación del ADN/efectos de los fármacos , Reparación del ADN/efectos de la radiación , Desoxiguanosina/análogos & derivados , Desoxiguanosina/metabolismo , Suplementos Dietéticos , Humanos , Inflamación/metabolismo , Inflamación/patología , Macrófagos/metabolismo , Masculino , Ratones , Mutagénesis/efectos de los fármacos , Mutagénesis/efectos de la radiación , Extractos Vegetales/administración & dosificación , Dímeros de Pirimidina/metabolismo , Piel/citología , Piel/efectos de los fármacos , Piel/metabolismo , Piel/efectos de la radiación , Proteína p53 Supresora de Tumor/metabolismo , Rayos UltravioletaRESUMEN
Acrodermatitis continua of Hallopeau (ACH) consists of a relapsing pustular eruption of the distal portions of hands and feet. We described a case of a 9-year-old boy affected by ACH, successfully treated with targeted ultraviolet B 311 nm phototherapy, which seems to be an effective and safe therapy for this condition.
Asunto(s)
Acrodermatitis/radioterapia , Epidermólisis Ampollosa Distrófica/radioterapia , Terapia Ultravioleta/métodos , Acrodermatitis/patología , Niño , Epidermólisis Ampollosa Distrófica/patología , Humanos , MasculinoRESUMEN
Erythroplasia of Queyrat (EQ) is an intraepidermal carcinoma in situ presenting clinically as a sharply demarcated, slightly raised erythematosus plaque on the glans penis or the inner side of the foreskin. Various treatment modalities for EQ have been proposed, including electrocautery and curettage, topical 5-floururacil cream, imiquimod cream, isotretinoin, cryotherapy, laser therapy, radiotherapy, ingenol mebutate gel and Photodynamic Therapy (PDT). Most of these treatments are limited by low clearance rates and frequent relapses. Surgical treatment including local excision, Mohs micrographic surgery and partial or total penectomy, ensures adequate healing rates. However, discomfort consequent to surgical treatment might be unacceptable. Topical PDT using the methyl ester of 5- aminolaevulinic acid (MAL) is an established non-surgical treatment of cutaneous precancerous lesions and skin cancers. We present the case of a 60-year-old uncircumcised man affected by EQ of the penis successfully treated with MAL-PDT, performed five times, two weeks apart, with no recurrences after 6 years.
RESUMEN
Treatment with thymidine dinucleotide (pTT) has well documented DNA-protective effects and reduces development of squamous cell carcinoma in UV-irradiated mice. The preventive effect of pTT on basal cell carcinoma (BCC) was evaluated in UV-irradiated Ptch-1(+/-) mice, a model of the human disease Gorlin syndrome. Topical pTT treatment significantly reduced the number and size (P < 0.001) of BCCs in murine skin after 7 months of chronic irradiation. Skin biopsies collected 24 hours after the final UV exposure showed that pTT reduced the number of nuclei positive for cyclobutane pyrimidine dimers by 40% (P < 0.0002) and for 8-hydroxy-2'-deoxyguanosine by 61% (P < 0.01 compared with vehicle control). Immunostaining with an antibody specific for mutated p53 revealed 63% fewer positive patches in BCCs of pTT-treated mice compared with controls (P < 0.01), and the number of Ki-67-positive cells was decreased by 56% (P < 0.01) in pTT-treated tumor-free epidermis and by 76% (P < 0.001) in BCC tumor nests (P < 0.001). Terminal dUTP nick-end labeling staining revealed a 213% increase (P < 0.04) in the number of apoptotic cells in BCCs of pTT-treated mice. Cox-2 immunostaining was decreased by 80% in tumor-free epidermis of pTT-treated mice compared with controls (P < 0.01). We conclude that topical pTT treatment during a prolonged period of intermittent UV exposure decreases the number and size of UV-induced BCCs through several anti-cancer mechanisms.
Asunto(s)
Anticarcinógenos/uso terapéutico , Carcinoma Basocelular/prevención & control , Receptores de Superficie Celular/fisiología , Neoplasias Cutáneas/prevención & control , Nucleótidos de Timina/uso terapéutico , Rayos Ultravioleta , 8-Hidroxi-2'-Desoxicoguanosina , Administración Cutánea , Animales , Anticarcinógenos/administración & dosificación , Apoptosis , Síndrome del Nevo Basocelular , Carcinoma Basocelular/metabolismo , Carcinoma Basocelular/patología , Núcleo Celular/efectos de los fármacos , Tamaño de la Célula , Desoxiguanosina/análogos & derivados , Desoxiguanosina/metabolismo , Humanos , Ratones , Receptores Patched , Receptor Patched-1 , Dímeros de Pirimidina/metabolismo , Receptores de Superficie Celular/genética , Piel/metabolismo , Piel/patología , Nucleótidos de Timina/administración & dosificaciónAsunto(s)
Dermoscopía , Nevo Pigmentado/patología , Neoplasias Cutáneas/patología , Femenino , Humanos , MasculinoRESUMEN
BACKGROUND: A single nucleotide polymorphism (61A>G) in the epidermal growth factor (EGF) gene has been implicated in both melanoma pathogenesis and increased melanoma risk. To further evaluate this association, we conducted a case-control study in a clinic-based Italian population. METHODS: Individuals with less than 10 (N = 127) or more than 100 (N = 128) benign nevi, and patients with cutaneous melanoma (N = 418) were investigated for the EGF +61A>G polymorphism, using an automated sequencing approach. RESULTS: Overall, no difference in EGF genotype frequencies was observed among subjects with different number of nevi as well as when non-melanoma healthy controls were compared with the melanoma patients. However, a heterogeneous distribution of the frequencies of the G/G genotype was detected among cases and controls originating from North Italy (21.1 and 18.3%, respectively) vs. those from South Italy (12.6 and 17.1%, respectively). CONCLUSION: Our findings further suggest that EGF +61A>G polymorphism may have a limited impact on predisposition and/or pathogenesis of melanoma and its prevalence may vary in different populations.
Asunto(s)
Factor de Crecimiento Epidérmico/genética , Melanoma/genética , Polimorfismo de Nucleótido Simple , Neoplasias Cutáneas/genética , Adulto , Femenino , Predisposición Genética a la Enfermedad/epidemiología , Genotipo , Humanos , Italia/epidemiología , Masculino , Melanoma/epidemiología , Persona de Mediana Edad , Prevalencia , Factores de Riesgo , Neoplasias Cutáneas/epidemiología , Adulto JovenRESUMEN
Subcorneal pustular dermatosis (SPD) [Sneddon-Wilkinson disease] is a benign and uncommon disorder characterized by a chronic, relapsing vesiculopustular eruption of unknown etiology. We present a case of SPD in a young Black woman in whom ELISA was performed to test for desmoglein 1 and 3 antigens (the first reported case of evaluation for these antigens in a patient with SPD). The test revealed the absence of both antibodies. The patient was successfully treated with topical corticosteroids and narrow-band UVB phototherapy. In this report, we review both the pathophysiology of SPD, which has yet to be clarified, and its treatment. Data obtained from our case report add further support to the hypothesis that a non-antibody-mediated mechanism is operative in SPD. The treatment of choice for SPD is dapsone. However, the combination of corticosteroids and UVB phototherapy should be considered a valid therapeutic option in patients who are not appropriate candidates for dapsone therapy.
Asunto(s)
Autoanticuerpos/sangre , Desmogleína 1/inmunología , Enfermedades Cutáneas Vesiculoampollosas/inmunología , Adulto , Dapsona/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Desmogleína 3/inmunología , Ensayo de Inmunoadsorción Enzimática , Femenino , Glucocorticoides/uso terapéutico , Humanos , Fototerapia , Piel/patología , Enfermedades Cutáneas Vesiculoampollosas/diagnóstico , Enfermedades Cutáneas Vesiculoampollosas/tratamiento farmacológico , Enfermedades Cutáneas Vesiculoampollosas/fisiopatologíaAsunto(s)
Carcinoma Basocelular/diagnóstico , Errores Diagnósticos , Errores de Medicación , Melanoma Amelanótico/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Adulto , Aminoquinolinas/uso terapéutico , Antineoplásicos/uso terapéutico , Carcinoma Basocelular/tratamiento farmacológico , Femenino , Humanos , Imiquimod , Melanoma Amelanótico/diagnóstico , Neoplasias Cutáneas/diagnósticoAsunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Inhibición de Migración Celular/efectos de los fármacos , Huésped Inmunocomprometido , Nevo Pigmentado/inmunología , Neoplasias Cutáneas/inmunología , Adulto , Anticuerpos Monoclonales Humanizados/administración & dosificación , Dermoscopía , Femenino , Humanos , Esclerosis Múltiple/tratamiento farmacológico , Natalizumab , TorsoAsunto(s)
Linfoma de Células del Manto/diagnóstico , Neoplasias Cutáneas/diagnóstico , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biopsia , Reordenamiento Génico de Linfocito B , Genes de las Cadenas Pesadas de las Inmunoglobulinas , Humanos , Inmunohistoquímica , Inmunofenotipificación , Linfoma de Células del Manto/tratamiento farmacológico , Linfoma de Células del Manto/inmunología , Linfoma de Células del Manto/patología , Masculino , Piel/inmunología , Piel/patología , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/patologíaRESUMEN
Darier's disease (DD) is an autosomal dominant inherited genodermatosis which is often under- or misdiagnosed. In the majority of cases, the disease manifests in adolescents or young adults with small brownish-yellow, warty, hyperkeratotic papules in multiple seborrheic areas of the body. Localized DD (LDD) is a clinical variant, first described by Kreibich in 1906; only a few cases are reported in the literature. We described the case of an aged woman presenting with LDD, and we review the literature on this subject.
RESUMEN
The induction of multiple eruptive melanocytic naevi has frequently been reported to occur in association with chemotherapy or immunosuppressive regimens, particularly in children and adolescents. We describe the dermoscopic features of eruptive melanocytic naevi in an adult non-transplanted patient receiving immunosuppressive therapy for Crohn's disease. By dermoscopy, we observed a peripheral rim of large brown globules in most of the lesions. We have previously identified a group of patients characterized by this dermoscopic feature. These patients were children, adolescents and young adults with renal allografts receiving immunosuppressive therapy. The findings of our case strongly suggest that this dermoscopic feature may be associated with eruptive naevi developed in association with immunosuppression from any cause.